CLRB News and Press, Cellectar Biosciences Inc. From 09/05/23

2023-09-05 13:07:33 ET Gainers: Helius Medical Technologies ( HSDT ) +a55% . Novo Integrated Sciences ( NVOS ) +38% . Shengfeng Development Limited ( SFWL ) +29% . Cibus ( CBUS ) +28% . Cellectar Biosciences ( CLRB ) +28% . C...

2023-09-05 12:14:58 ET Cellectar Biosciences ( NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company, Tuesday said it has entered into a securities purchase agreement with certain institutional investors for a private placement financing that is expected to result in gro...

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is one today's most active stocks by volume. So far today, approximately 29.61M shares of Cellectar Biosciences, Inc. have been exchanged, as compared to an average 30-day volume of 17,273 shares. Cellectar Biosciences, Inc., a clinical biopharmaceuti...

2023-09-05 10:00:14 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 F...

2023-08-14 11:18:55 ET Cellectar Biosciences press release ( NASDAQ: CLRB ): Q2 GAAP EPS of -$0.73. As of June 30, 2023, the company had cash and cash equivalents of $5.2 million, compared to $19.9 million as of December 31, 2022. For further details see: Ce...

FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter end...

Interim data from 64 refractory multiple myeloma patients demonstrated an ORR of 28%, a CBR of 70%, and a DCR of 92% Demonstrated a 46% ORR in triple class refractory, 50% ORR in quad-class refractory and 50% ORR in post-BCMA treated patients FLORHAM PARK, N.J., June 28, 2023 ...

Waldenstrom’s macroglobulinemia pivotal trial top-line data now expected second half of 2023; pediatric high-grade glioma trial to initiate in Q3 Phospholipid drug conjugate platform validation with alpha-emitting radioisotopes, small molecules, peptides and oligos FLOR...

2023-05-04 10:10:06 ET Cellectar Biosciences press release ( NASDAQ: CLRB ): Q1 GAAP EPS of -$0.76. As of March 31, 2023, the company had cash and cash equivalents of $12.7 million, compared to $19.9 million as of December 31, 2023. For further details see: ...